Laura Lisk

2.0k total citations · 2 hit papers
17 papers, 1.3k citations indexed

About

Laura Lisk is a scholar working on Rheumatology, Nephrology and Hepatology. According to data from OpenAlex, Laura Lisk has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 9 papers in Nephrology and 8 papers in Hepatology. Recurrent topics in Laura Lisk's work include Systemic Lupus Erythematosus Research (11 papers), Liver Diseases and Immunity (5 papers) and Renal Diseases and Glomerulopathies (5 papers). Laura Lisk is often cited by papers focused on Systemic Lupus Erythematosus Research (11 papers), Liver Diseases and Immunity (5 papers) and Renal Diseases and Glomerulopathies (5 papers). Laura Lisk collaborates with scholars based in United States, Netherlands and Germany. Laura Lisk's co-authors include Neil Solomons, Ellen M. Ginzler, David Isenberg, David Wofsy, David Jayne, Mary Anne Dooley, Gerald B. Appel, Frank Eitner, Nancy J. Olsen and Gabriel Contreras and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Kidney International.

In The Last Decade

Laura Lisk

17 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

2011 421 citations Mary Anne Dooley, David Jayne et al. New England Journal of Medicine profile →
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

2021 299 citations Brad H. Rovin, Y K Onno Teng et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Lisk United States	12	943	759	344	266	218	17	1.3k
Mirella Alpa Italy	18	313 0.3×	378 0.5×	133 0.4×	187 0.7×	78 0.4×	28	1.1k
Juan M. Mejía‐Vilet Mexico	19	525 0.6×	498 0.7×	310 0.9×	126 0.5×	74 0.3×	54	1.0k
Roberta Fenoglio Italy	19	254 0.3×	374 0.5×	140 0.4×	75 0.3×	53 0.2×	89	997
Wan-zhong Zou China	17	421 0.4×	737 1.0×	237 0.7×	45 0.2×	66 0.3×	49	1.2k
Maria-Victoria Egurbide Spain	9	721 0.8×	66 0.1×	241 0.7×	54 0.2×	99 0.5×	9	951
Adnan N. Kiani United States	18	804 0.9×	128 0.2×	603 1.8×	39 0.1×	136 0.6×	27	1.0k
Fernando Nolasco Portugal	12	114 0.1×	462 0.6×	187 0.5×	73 0.3×	33 0.2×	88	831
Giacomo Quattrocchio Italy	17	163 0.2×	421 0.6×	115 0.3×	41 0.2×	68 0.3×	52	836
Zhen Qu China	18	240 0.3×	673 0.9×	246 0.7×	45 0.2×	42 0.2×	44	920
Louise Oni United Kingdom	15	245 0.3×	297 0.4×	210 0.6×	25 0.1×	46 0.2×	46	641

Countries citing papers authored by Laura Lisk

Since Specialization

Citations

This map shows the geographic impact of Laura Lisk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Lisk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Lisk more than expected).

Fields of papers citing papers by Laura Lisk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Lisk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Lisk. The network helps show where Laura Lisk may publish in the future.

Co-authorship network of co-authors of Laura Lisk

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Lisk. A scholar is included among the top collaborators of Laura Lisk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Lisk. Laura Lisk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Saxena, Amit, Ellen M. Ginzler, Keisha L. Gibson, et al.. (2023). Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis & Rheumatology. 76(1). 59–67. 49 indexed citations

McDonald, Stephen, Li Su, Caroline Gordon, et al.. (2022). Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Science & Medicine. 9(1). e000584–e000584. 8 indexed citations

Teng, Y K Onno, et al.. (2022). FC054: Voclosporin for Lupus Nephritis: Results of the Two-Year Aurora 2 Continuation Study. Nephrology Dialysis Transplantation. 37(Supplement_3). 2 indexed citations

Arriens, Cristina, Y K Onno Teng, Ellen M. Ginzler, et al.. (2022). Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care & Research. 75(7). 1399–1408. 24 indexed citations

Rovin, Brad H., Y K Onno Teng, Ellen M. Ginzler, et al.. (2021). Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 397(10289). 2070–2080. 299 indexed citations breakdown →

Gelder, Teun van, Robert B. Huizinga, Laura Lisk, & Neil Solomons. (2021). Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. Nephrology Dialysis Transplantation. 37(5). 917–922. 21 indexed citations

Gelder, Teun van, et al.. (2020). Use of Therapeutic Drug Monitoring Does Not Add Clinical Value for Voclosporin in Patients with Lupus Nephritis. Journal of the American Society of Nephrology. 31(10S). 594–594. 8 indexed citations

Floege, Jürgen, Adrian Covic, Markus Ketteler, et al.. (2016). One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation. 32(11). 1918–1926. 22 indexed citations

Covic, Adrian, Jürgen Floege, Markus Ketteler, et al.. (2016). Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation. 32(8). 1330–1338. 42 indexed citations

10.

Floege, Jürgen, Adrian Covic, Markus Ketteler, et al.. (2015). Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation. 30(6). 1037–1046. 101 indexed citations

11.

Floege, Jürgen, Adrian Covic, Markus Ketteler, et al.. (2014). A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney International. 86(3). 638–647. 143 indexed citations

12.

Walsh, Michael, Neil Solomons, Laura Lisk, & David Jayne. (2013). Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study. American Journal of Kidney Diseases. 61(5). 710–715. 48 indexed citations

13.

Sundel, Robert P., et al.. (2012). Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 21(13). 1433–1443. 34 indexed citations

14.

Dooley, Mary Anne, David Jayne, Ellen M. Ginzler, et al.. (2011). Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine. 365(20). 1886–1895. 421 indexed citations breakdown →

15.

Wofsy, David, et al.. (2010). Nonrenal Disease Activity Following Mycophenolate Mofetil or Intravenous Cyclophosphamide as Induction Treatment for Lupus Nephritis. UCL Discovery (University College London). 1 indexed citations

16.

Ginzler, Ellen M., et al.. (2009). Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open‐label, parallel‐group clinical trial. Arthritis & Rheumatism. 62(1). 211–221. 88 indexed citations

17.

Dowson, Andrew, Laura Lisk, Chris Webster, & Mary S. Richardson. (2004). Long-term Use of Sumatriptan Nasal Spray is Well-tolerated in Adolescent Migraineurs. 1(1). 66–68. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact